The United States Food and Drug Administration (FDA) granted approval on October 9, 2026, for Hovilpri (pritelivir), a tablet medication aimed at treating lesions caused by the herpes simplex virus in immunocompromised adults who have not responded to acyclovir, valacyclovir, or famciclovir treatments.
This approval presents a new option for patients with weakened immune systems, who may experience more frequent and severe outbreaks. However, it is essential to note that Hovilpri is not a cure for herpes; its purpose is to address the lesions, not to eradicate the virus from the body.
Targeted Treatment for Mucocutaneous Lesions
According to the FDA's official announcement, Hovilpri is designated for mucocutaneous lesions, which affect the skin or mucous membranes, including areas like the lips, nostrils, eyes, and genitals.
Clinical Trial Results and Efficacy
The approval is supported by data from phase 3 of the PRIOH-1 clinical trial, part C, which involved 101 immunocompromised adults with herpes simplex virus lesions unresponsive to the specified antivirals. Participants were randomly assigned to receive either Hovilpri or one of the investigator-chosen existing treatments. The study was open-label, meaning both participants and medical teams were aware of the treatment administered.
The primary measure of success was the proportion of patients whose lesions completely healed within the first 28 days of treatment. Among those treated with Hovilpri, 63% achieved complete healing, compared to 34% of those on investigator-selected alternatives, as reported by the FDA.
Treatment could be extended up to 42 days if lesions showed improvement by day 28 but had not fully healed. These results are specific to the studied population and should not be generalized as proven efficacy for all individuals with herpes.
Understanding the Approval and Safety Considerations
Among the participants were individuals with various conditions affecting immune defenses, including HIV infections, cancer, autoimmune disorders, and transplant histories.
Herpes simplex, caused by HSV-1 and HSV-2 viruses, can lead to painful blisters or ulcers. After initial infection, the virus can become dormant and reactivate, sometimes shedding virus without symptoms. Thus, healing of lesions does not signify the infection's absence.
The FDA granted Hovilpri priority review for this specific indication. The decision is limited to immunocompromised adults with lesions unresponsive to the specified antivirals and does not extend to all herpes episodes.
In terms of safety, the FDA noted that headaches were the most common adverse reaction and warned of potential interactions with other medications. Healthcare professionals are advised to refer to the official prescription information before administering Hovilpri.
FAQs about Hovilpri Approval and Usage
What is the primary use of Hovilpri?
Hovilpri is primarily used to treat herpes simplex virus lesions in immunocompromised adults that are resistant to traditional antiviral treatments.
Does Hovilpri cure herpes?
No, Hovilpri is not a cure for herpes. It is designed to address and heal lesions caused by the virus but does not eliminate the virus from the body.
Are there any common side effects associated with Hovilpri?
The most commonly reported side effect of Hovilpri is a headache. The FDA also warns of potential interactions with other medications.